MedTrace Logo

Simplified Antiviral Treatment Strategy for Hepatitis C in Ukraine

NCT04038320 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 868

Last updated 2019-07-30

No results posted yet for this study

Summary

The project will evaluate cost and treatment outcomes of a simplified Hepatitis C Virus (HCV) testing, treatment and care model integrated with HIV testing and treatment among key affected populations in Ukraine.

Conditions

  • Hepatitis C Virus

Interventions

DRUG

Sofosbuvir/ledipasvir (SOF/LDV)

SOF/LDV (400mg/90mg) orally once daily with or without food in the morning and will receive treatment for a duration of 12 weeks. In addition, Ribavirin weight-based (1000 mg for patients \<75 kg and 1200 mg for those ≥75 kg) administered orally in two divided doses with food for Genotype 3 patients.

Sponsors & Collaborators

  • All Ukrainian Network of PLHA

    collaborator UNKNOWN

  • Public Health Center of MOH Ukraine

    collaborator UNKNOWN

  • Alliance for the Public's Health

    collaborator OTHER

  • Boston University

    collaborator OTHER

  • University of California, Los Angeles

    collaborator OTHER

  • Right to Care

    lead OTHER

Principal Investigators

  • Ian Sanne, MBBCH, FRCP · Right to Care

  • Svetlana Antonyak, MD · Hepatitis and HIV-infection of Institute of Epidemiology and Infectious Diseases of L.V. Gromashevskiy of NAMS of Ukraine

  • Tetiana Benard, MA · Right to Care, Ukraine

  • Charles Chasela, PhD · Right to Care

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-26
Primary Completion
2019-03-30
Completion
2019-06-30
FDA Drug
Yes

Countries

  • Ukraine

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04038320 on ClinicalTrials.gov